Bone, cartilage and hormone therapy: Established concepts and future scenarios

Climacteric

Volumn 10, Issue 4, 2007, Pages 270-272

  Holinka, C F ^a   Karsdal, M A ^b   Christiansen, C ^c  

^a PharmConsult   (United States)

^b NORDIC BIOSCIENCE A S   (Denmark)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone; Cartilage; Estrogen; Hormone therapy; Intervertebral disc height; Osteoporosis; Postmenopause

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE MASS; BREAST CANCER; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DRUG DOSE COMPARISON; EDITORIAL; FRACTURE REDUCTION; HEALTH CARE PERSONNEL; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; MONOTHERAPY; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; VAGINA ATROPHY; VASOMOTOR DISORDER;

BIOLOGICAL MARKERS; BONE REMODELING; CARTILAGE; COLLAGEN TYPE I; FEMALE; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; INTERVERTEBRAL DISK; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 34547148069     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701511202     Document Type: Editorial

References (19)

1. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53
2. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12
3. Gambacciani M, Ciaponi M, Genazzani AR. The HRT misuse and the osteoporosis epidemic: a possible future scenario. Climacteric 2007;10:273-5
4. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
6. Bagger YZ, Tankó L, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-35
7. Bagger YZ, Tankó L, Alexandersen P, Qin G, Christiansen C, for the PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005;12:12-17
8. Muscat Baron Y, Brincat MB, Galea R, Calleja N. Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures. Climacteric 2007;10:314-19
9. Ausmanas MK, Holinka CF, Yu SL, Christiansen C. Effects of three doses of conjugated estrogens/medroxyprogesteone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. Climacteric 2007;10:306-13
10. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The PAN-Asia Menopause (PAM) study. Maturitas 2005;52:35-51
11. Taechakraichana N, Holinka CF, Haines CJ, Subramaniam R, Tian XW, Ausmanas M. Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study. Climacteric 2007;10:225-37
12. Karsdal MA, Tanko LB, Riis BJ, et al. Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA? Osteoarthritis Cartilage 2006;14:617-24
13. Sorensen MG, Henriksen K, Dziegiel MH, Tanko LB, Karsdal MA. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 2006;25:475-83
14. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006;54:2441-51
15. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002;46:1956-64
16. Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15
17. Reijman M, Hazes JMW, Bierma-Zeinstra SMA, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-8
18. Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006;65:1639-44
19. Christgau S, Tanko LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004;11:508-18